---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013631"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:23:23.444608+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain

## Summary
- All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.
- 100% of responding patients zero opioid use at 7 days post-procedure; 73% remained opioid-free at 4-6 weeks follow-up.
- No device- or procedure-related serious adverse events; 6 subjects died from disease progression unrelated to the procedure.
- PoC2 phase begins Q2 2025, targeting additional visceral cancers (liver, gall bladder, bile duct) and earlier-stage pancreatic cancer.

## SEC filing metadata
- accession: 0001437749-25-013631
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/0001437749-25-013631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/amix20250429_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013631
- JSON: https://secwatch.observer/filing/0001437749-25-013631.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.